INVO Fertility operates fertility clinics in the United States and sells its proprietary INVOcell medical device. The company's primary commercial focus is its clinic segment, which owns and operates facilities providing assisted reproductive services including in vitro fertilization (IVF), intrauterine insemination, and fertility preservation. These clinics also offer a specialized intravaginal culture procedure enabled by the INVOcell device. Unlike conventional IVF that uses laboratory incubators, the INVOcell device allows fertilization and early embryo development to occur inside the woman’s body. INVO Fertility argues this method provides outcomes equivalent to IVF at a lower cost and with a more natural patient experience. The company’s business model derives revenue from treatment cycles at its clinics and per-unit device sales to third-party providers, though clinic operations are the dominant revenue driver. INVO Fertility pursues growth by acquiring established, profitable clinics to immediately capture patient volume and cash flow, as seen with its acquisitions of Wisconsin Fertility Institute and Family Beginnings. The company also establishes joint venture clinics in underserved secondary markets. INVO Fertility maintains a centralized corporate structure and outsources the manufacturing and logistics for its medical devices to contract manufacturers. The company recently refocused its operations exclusively on fertility services after divesting other therapeutic interests.